More about

Lenalidomide

News
January 08, 2020
4 min read
Save

Luspatercept reduces transfusion burden for certain patients with lower-risk myelodysplastic syndrome

Luspatercept reduced the severity of anemia compared with placebo among certain patients with lower-risk myelodysplastic syndromes, according to results of a randomized phase 3 trial published in The New England Journal of Medicine.

News
December 12, 2019
2 min read
Save

Novel therapy combination effective in large cell lymphoma

ORLANDO – Combining all novel drugs – rituximab, lenalidomide and ibrutinib – to treat diffuse large B-cell lymphoma proved more effective than standard chemotherapy and combinations thereof, according to a poster presenter at the ASH Annual Meeting and Exposition.

News
December 11, 2019
3 min read
Save

Lenalidomide plus obinutuzumab effective in relapsed low-grade lymphoma

ORLANDO — Combining lenalidomide with obinutuzumab in relapsed indolent lymphoma produced high overall response even in refractory patients and those who failed multiple lines of treatment, according to a presenter at the ASH Annual Meeting and Exposition.

News
December 10, 2019
6 min watch
Save

Polatuzumab vedotin plus obinutuzumab, lenalidomide shows promise in R/R follicular lymphoma

ORLANDO — Catherine Diefenbach, MD, director of the clinical lymphoma program and of hematology translational research, Perlmutter Cancer Center at NYU Langone Health, presented efficacy and safety data from a phase 1b/2 study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma at ASH Annual Meeting & Exposition.

News
December 09, 2019
4 min read
Save

Daratumumab regimen increases response in transplant-eligible multiple myeloma

ORLANDO — The addition of daratumumab to lenalidomide, bortezomib and dexamethasone significantly improved rates of stringent clinical response and minimal disease negativity among patients with transplant-eligible newly diagnosed multiple myeloma, according to results of the randomized phase 2 GRIFFIN study presented at ASH Annual Meeting and Exposition.

News
December 09, 2019
5 min read
Save

Three-agent regimen effective, safe in high-risk smoldering multiple myeloma

ORLANDO — The combination of ixazomib, lenalidomide and dexamethasone appeared highly effective for patients with high-risk smoldering myeloma, according to phase 2 study results presented at ASH Annual Meeting and Exposition.

News
August 28, 2019
3 min read
Save

Triplet therapy active in diffuse large B-cell lymphoma

The combination of ibrutinib, lenalidomide and rituximab demonstrated robust, ongoing activity among patients with relapsed or refractory diffuse large B-cell lymphoma, especially those with nongerminal center B-cell DLBCL, according to results of the dose-escalation portion of a phase 1b/phase 2 study published in Blood.

News
July 26, 2023
3 min watch
Save

VIDEO: Treatment considerations for relapsed, refractory follicular lymphoma

In this video, Noah Merin, MD, PhD, from the Blood and Marrow Transplantation Program and assistant professor of medicine at Cedars-Sinai Medical Center, discussed first-line treatments and options for relapsed or refractory follicular lymphoma.

News
February 01, 2024
3 min watch
Save

VIDEO: Discussing common questions about CAR T-cell therapy with myeloma patients

In this video, Saad Usmani, MD, a myeloma specialist at Memorial Sloan Kettering Cancer Center, discusses how he addresses some of the common questions he hears from multiple myeloma patients about CAR T-cell therapy.

View more